Gemini Therapeutics, Inc. (NASDAQ:GMTX – Get Free Report)’s share price shot up 1% during trading on Wednesday . The stock traded as high as $55.89 and last traded at $54.63. 310,440 shares traded hands during trading, an increase of 64% from the average session volume of 189,291 shares. The stock had previously closed at $54.10.
Gemini Therapeutics Stock Performance
The firm’s 50-day simple moving average is $59.66 and its 200 day simple moving average is $54.94. The company has a market cap of $2.37 billion, a P/E ratio of -54.63 and a beta of -0.12.
Gemini Therapeutics Company Profile
Gemini Therapeutics, Inc, a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients.
Further Reading
- Five stocks we like better than Gemini Therapeutics
- Investing in Construction Stocks
- Nebius Group: NVIDIA’s Investment Sparks All-Time Highs
- How to Invest in Biotech Stocks
- SoFi Stock Rallying Strong in the Last 5 Days—What’s Driving It?
- Insider Trading – What You Need to Know
- Intel Surges on M&A Talks: Rally Beginning or Just a Headfake?
Receive News & Ratings for Gemini Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gemini Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
